Rapamycin slows IgA nephropathy progression in the rat

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• IgA nephropathy (IgAN) is a prevalent glomerular disease globally.
• Existing therapeutic strategies for IgAN are diverse.
• This study investigates the protective effects of low-dose rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, in an IgAN rat model.

Purpose of the Study:

• To evaluate the renoprotective potential of low-dose rapamycin in an IgAN rat model.
• To elucidate the underlying mechanisms of rapamycin's action in IgAN.

Main Methods:

• Establishment of an IgAN rat model followed by random group assignment (control, control + rapamycin, IgAN, IgAN + rapamycin).
• Assessment of proteinuria, hepatic and renal function, and cell proliferation (5-bromo-2'-deoxyuridine incorporation).
• Analysis of gene and protein expression for fibrosis markers (α-SMA, collagen I, collagen III), growth factors (TGF-β1, platelet-derived growth factor), and mTOR pathway activity (p-S6).

Main Results:

• Low-dose rapamycin mitigated proteinuria and preserved kidney function in IgAN rats.
• Rapamycin reduced IgA deposition and inhibited cell proliferation.
• Rapamycin decreased the expression of fibrosis markers (α-SMA, type III collagen) and profibrotic factors (PDGF, TGF-β1).
• Elevated p-S6 protein levels indicated mTOR pathway activation in IgAN rats.

Conclusions:

• The mammalian target of rapamycin (mTOR) pathway is activated in IgA nephropathy (IgAN).
• Early intervention with low-dose rapamycin demonstrates potential to attenuate renal injury in IgAN.
• Rapamycin interferes with critical pathways contributing to IgAN progression to end-stage renal disease.